Erratum: "Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors" (Molecular Theraphy (2009) 10.1038/mt.2009.152);Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors

Molecular Therapy

Volumn 17, Issue 10, 2009, Pages 1683-1691

  Greig, Jenny A ^a   Buckley, Suzanne M K ^b   Waddington, Simon N ^b   Parker, Alan L ^a   Bhella, David ^c   Pink, Rebecca ^c   Rahim, Ahad A ^b   Morita, Takashi ^d   Nicklin, Stuart A ^a   McVey, John H ^e   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^e THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BINDING PROTEIN; BLOOD CLOTTING FACTOR 10; CHIMERIC ADENOVIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ADENOVIRUS 35; ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PROTEIN BINDING; SEROTYPE; SURFACE PLASMON RESONANCE; TARGET ORGAN; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS MORPHOLOGY;

HUMAN ADENOVIRUS TYPE 5; MUS MUSCULUS;

EID: 70349869162     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.186     Document Type: Erratum

References (50)

1. Abbink, P, Lemckert, AA, Ewald, BA, Lynch, DM, Denholtz, M, Smits, S et al. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
2. Sumida, SM, Truitt, DM, Lemckert, AA, Vogels, R, Custers, JH, Addo, MM et al. (2005). Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
3. Sprangers, MC, Lakhai, W, Koudstaal, W, Verhoeven, M, Koel, BF, Vogels, R et al. (2003). Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41: 5046-5052.
4. Christ, M, Lusky, M, Stoeckel, F, Dreyer, D, Dieterlé, A, Michou, AI et al. (1997). Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 57: 19-25.
5. Vogels, R, Zuijdgeest, D, van Rijnsoever, R, Hartkoorn, E, Damen, I, de Béthune, MP et al. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271.
6. Parker, AL, Waddington, SN, Buckley, SM, Custers, J, Havenga, MJ, van Rooijen, N et al. (2009). Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol 83: 479-483.
7. Parker, AL, Waddington, SN, Nicol, CG, Shayakhmetov, DM, Buckley, SM, Denby, L et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108: 2554-2561.
8. Waddington, SN, Parker, AL, Havenga, M, Nicklin, SA, Buckley, SM, McVey, JH et al. (2007). Targeting of adenovirus serotype 5 (Ad5) and 5/ 47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 81: 9568-9571.
9. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
10. Subr, V, Kostka, L, Selby-Milic, T, Fisher, K, Ulbrich, K, Seymour, LW et al. (2009). Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release 135: 152-158.
11. Nicol, CG, Graham, D, Miller, WH, White, SJ, Smith, TA, Nicklin, SA et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 10: 344-354.
12. Carlisle, RC, Di, Y, Cerny, AM, Sonnen, AF, Sim, RB, Green, NK et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113: 1909-1918.
13. Stone, D, Liu, Y, Shayakhmetov, D, Li, ZY, Ni, S and Lieber, A (2007). Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol 81: 4866-4871.
14. Hofherr, SE, Mok, H, Gushiken, FC, Lopez, JA and Barry, MA (2007). Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther 18: 837-848.
15. Raper, SE, Chirmule, N, Lee, FS, Wivel, NA, Bagg, A, Gao, GP et al. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158.
16. Bergelson, JM, Cunningham, JA, Droguett, G, Kurt-Jones, EA, Krithivas, A, Hong, JS et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
17. Tomko, RP, Xu, R and Philipson, L (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356.
18. Wickham, TJ, Mathias, P, Cheresh, DA and Nemerow, GR (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
19. Nicklin, SA, Wu, E, Nemerow, GR and Baker, AH (2005). The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 12: 384-393.
20. Alemany, R and Curiel, DT (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 8 1347-1353.
21. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488.
22. Parker, AL, McVey, JH, Doctor, JH, Lopez-Franco, O, Waddington, SN, Havenga, MJ et al. (2007). Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol 81: 3627-3631.
23. Havenga, MJ, Lemckert, AA, Ophorst, OJ, van Meijer, M, Germeraad, WT, Grimbergen, J et al. (2002). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 76: 4612-4620.
24. Gaggar, A, Shayakhmetov, DM and Lieber, A (2003). CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412.
25. Havenga, MJ, Lemckert, AA, Grimbergen, JM, Vogels, R, Huisman, LG, Valerio, D et al. (2001). Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75: 3335-3342.
26. Ni, S, Gaggar, A, Di Paolo, N, Li, ZY, Liu, Y, Strauss, R et al. (2006). Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther 13: 1072-1081.
27. Kinugasa, N, Higashi, T, Nouso, K, Nakatsukasa, H, Kobayashi, Y, Ishizaki, M et al. (1999). Expression of membrane cofactor protein (MCP, CD46) in human liver diseases. Br J Cancer 80: 1820-1825.
28. Murray, KP, Mathure, S, Kaul, R, Khan, S, Carson, LF, Twiggs, LB et al. (2000). Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 76: 176-182.
29. Shayakhmetov, DM, Eberly, AM, Li, ZY and Lieber, A (2005). Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol 79: 1053-1061.
30. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381.
31. Wang, H, Liu, Y, Li, Z, Tuve, S, Stone, D, Kalyushniy, O et al. (2008). In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol 82: 10567-10579.
32. Brouwer, E, Havenga, MJ, Ophorst, O, de Leeuw, B, Gijsbers, L, Gillissen, G et al. (2007). Human adenovirus type 35 vector for gene therapy of brain cancer: Improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 14: 211-219.
33. DiPaolo, N, Ni, S, Gaggar, A, Strauss, R, Tuve, S, Li, ZY et al. (2006). Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther 13: 756-765.
34. Sakurai, F, Mizuguchi, H, Yamaguchi, T and Hayakawa, T (2003). Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 8: 813-821.
35. Shayakhmetov, DM, Li, ZY, Ni, S and Lieber, A (2002). Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 62: 1063-1068.
36. Shinozaki, K, Suominen, E, Carrick, F, Sauter, B, Kähäri, VM, Lieber, A et al. (2006). Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Ther 13: 52-59.
37. Stone, D, Liu, Y, Li, ZY, Tuve, S, Strauss, R and Lieber, A (2007). Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther 15: 2146-2153.
38. Tuve, S, Wang, H, Ware, C, Liu, Y, Gaggar, A, Bernt, K et al. (2006). A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 80: 12109-12120.
39. Inoue, N, Ikawa, M, Nakanishi, T, Matsumoto, M, Nomura, M, Seya, T et al. (2003). Disruption of mouse CD46 causes an accelerated spontaneous acrosome reaction in sperm. Mol Cell Biol 23: 2614-2622.
40. Bernt, KM, Ni, S, Gaggar, A, Li, ZY, Shayakhmetov, DM and Lieber, A (2003). The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 8: 746-755.
41. Baker, AH, Mcvey, JH, Waddington, SN, Di Paolo, NC and Shayakhmetov, DM (2007). The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther 15: 1410-1416.
42. Sakurai, F (2008). Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. Biol Pharm Bull 31 1819-1825.
43. Sakurai, F, Kawabata, K, Koizumi, N, Inoue, N, Okabe, M, Yamaguchi, T et al. (2006). Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice. Gene Ther 13: 1118-1126.
44. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
45. Miyazawa, N, Leopold, PL, Hackett, NR, Ferris, B, Worgall, S, Falck-Pedersen, E et al. (1999). Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol 73: 6056-6065.
46. Shayakhmetov, DM, Li, ZY, Ternovoi, V, Gaggar, A, Gharwan, H and Lieber, A (2003). The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 77: 3712-3723.
47. Verhaagh, S, de Jong, E, Goudsmit, J, Lecollinet, S, Gillissen, G, de Vries, M et al. (2006). Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 87(Pt 2): 255-265.
48. Tuve, S, Wang, H, Jacobs, JD, Yumul, RC, Smith, DF and Lieber, A (2008). Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog 4: E1000189.
49. Atoda, H, Ishikawa, M, Mizuno, H and Morita, T (1998). Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein. Biochemistry 37: 17361-17370.
50. Adrian, M, Dubochet, J, Lepault, J and McDowall, AW (1984). Cryo-electron microscopy of viruses. Nature 308: 32-36.